Mahmood Ahmad
Tahir Heart Institute
author@example.com

Protocol: CT.gov Sponsor Excess Watchlist

This protocol ranks named lead sponsors within eligible older closed interventional ClinicalTrials.gov studies after reusing the study-mix-adjusted no-results and ghost-protocol models from wave eight. Primary outputs compare sponsor-level excess no-results stock, excess ghost stock, black-box stock, overdue depth, and strict U.S.-nexus spillover. The aim is to move from broad sector tables to named repeater systems without discarding study-mix adjustment. Because sponsorship is registry-entered, these watchlists describe registry-visible lead sponsors rather than audited corporate or institutional control chains.

Outside Notes

Type: protocol
Primary estimand: Adjusted excess no-results and ghost-protocol stock among named lead sponsors with at least 100 older studies
App: CT.gov Sponsor Excess Watchlist dashboard
Code: https://github.com/mahmood726-cyber/ctgov-sponsor-excess-watchlist
Date: 2026-03-29
Validation: FULL REGISTRY RUN

References

1. ClinicalTrials.gov API v2. National Library of Medicine. Accessed March 29, 2026.
2. DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet. 2020;395(10221):361-369.
3. Zarin DA, Tse T, Williams RJ, Carr S. Trial reporting in ClinicalTrials.gov. N Engl J Med. 2016;375(20):1998-2004.

AI Disclosure

This work represents a compiler-generated evidence micro-publication built from structured registry data and deterministic summary code. AI was used as a constrained coding and drafting assistant for interface generation, packaging, and prose refinement, not as an autonomous author. The analytical choices, interpretation, and final outputs were reviewed by the author, who takes responsibility for the content.